INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 128 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2016. The put-call ratio across all filers is 3.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $11,752,884 | -0.6% | 171,600 | +0.4% | 0.01% | 0.0% |
| Q1 2024 | $11,826,280 | -3.1% | 170,900 | +0.3% | 0.01% | -11.1% |
| Q4 2023 | $12,204,048 | +23.4% | 170,400 | -10.2% | 0.01% | +12.5% |
| Q3 2023 | $9,886,682 | -16.4% | 189,800 | +1.7% | 0.01% | 0.0% |
| Q2 2023 | $11,821,844 | +18.7% | 186,700 | +1.5% | 0.01% | +14.3% |
| Q1 2023 | $9,958,185 | -8.3% | 183,900 | -10.4% | 0.01% | -12.5% |
| Q4 2022 | $10,859,184 | +15.9% | 205,200 | +1.9% | 0.01% | +14.3% |
| Q3 2022 | $9,366,000 | -16.2% | 201,300 | +2.8% | 0.01% | -12.5% |
| Q2 2022 | $11,176,000 | -5.7% | 195,800 | +1.1% | 0.01% | +14.3% |
| Q1 2022 | $11,846,000 | +48.8% | 193,600 | +27.3% | 0.01% | +40.0% |
| Q4 2021 | $7,961,000 | +40.0% | 152,100 | -0.3% | 0.01% | +25.0% |
| Q3 2021 | $5,685,000 | -8.1% | 152,500 | +0.6% | 0.00% | 0.0% |
| Q2 2021 | $6,188,000 | +10.7% | 151,600 | -8.0% | 0.00% | 0.0% |
| Q1 2021 | $5,592,000 | +9.2% | 164,800 | +2.3% | 0.00% | 0.0% |
| Q4 2020 | $5,123,000 | +23.9% | 161,100 | 0.0% | 0.00% | +33.3% |
| Q3 2020 | $4,134,000 | +20.1% | 161,100 | +20.1% | 0.00% | 0.0% |
| Q2 2020 | $3,442,000 | +96.6% | 134,100 | +17.7% | 0.00% | +50.0% |
| Q1 2020 | $1,751,000 | -43.1% | 113,900 | +27.0% | 0.00% | -33.3% |
| Q4 2019 | $3,078,000 | +374.3% | 89,700 | +3.2% | 0.00% | +200.0% |
| Q3 2019 | $649,000 | -42.5% | 86,900 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,128,000 | +16.0% | 86,900 | +8.9% | 0.00% | 0.0% |
| Q1 2019 | $972,000 | +10.2% | 79,800 | +3.1% | 0.00% | 0.0% |
| Q4 2018 | $882,000 | -45.3% | 77,400 | +4.2% | 0.00% | -50.0% |
| Q3 2018 | $1,612,000 | +22.8% | 74,300 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,313,000 | -16.0% | 74,300 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $1,564,000 | +54.7% | 74,300 | +6.4% | 0.00% | +100.0% |
| Q4 2017 | $1,011,000 | -8.2% | 69,800 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,101,000 | +66.3% | 69,800 | +31.0% | 0.00% | 0.0% |
| Q2 2017 | $662,000 | -23.6% | 53,300 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $866,000 | +7.7% | 53,300 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $804,000 | -1.0% | 53,300 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $812,000 | -61.8% | 53,300 | -2.6% | 0.00% | -66.7% |
| Q2 2016 | $2,123,000 | +44.5% | 54,700 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,469,000 | -31.5% | 54,700 | +37.1% | 0.00% | -40.0% |
| Q4 2015 | $2,146,000 | +34.3% | 39,900 | 0.0% | 0.01% | +25.0% |
| Q3 2015 | $1,598,000 | +105.9% | 39,900 | +64.2% | 0.00% | +100.0% |
| Q2 2015 | $776,000 | +33.8% | 24,300 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $580,000 | +93.3% | 24,300 | +42.9% | 0.00% | +100.0% |
| Q4 2014 | $300,000 | +28.8% | 17,000 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $233,000 | -18.8% | 17,000 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $287,000 | – | 17,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |